Clinical outcome
| R115777 dose (mg) . | Patient no. . | Diagnosis . | % Marrow blasts . | Total no. courses . | Clinical outcome . | Survival from R115777 (mo) . | |
|---|---|---|---|---|---|---|---|
| Pre-Rx . | End . | ||||||
| 100 | 1 | M5 | 95 | 95 | 1 | NR | 2.5 |
| 2 | M1 | 37 | 4 | 3 | CR 7 mo | 15 + | |
| 3 | CML-BC | 37 | 51 | 1 | NR | 6 | |
| 4 | M7 ? | NE | NE | 1 | NR | 5 | |
| 5 | M1 | 100 | 100 | 1 | NR | 1 | |
| 6 | M1 | 20 | 8 | 4 | PR | 14 + | |
| 300 | 7 | CML-BC | 39 | 7 | 3 | PR | 14.5 + |
| 8 | Ph + L2 | 80 | > 95 | 1 | NR | 5 | |
| 9 | L2 | 39 | 86 | 1 | NR | 1.5 | |
| 10 | M4 | 25 | 8 | 4 | PR | 7 | |
| 11 | M7 | 25 | 25 | 3 | NR | 5.5 | |
| 600 | 12 | M1 | 36 | 88 | 1 | NR | 0.5 |
| 13 | M4 | 83 | 64 | 1 | NR | 7 | |
| 14 | L2 | 90 | 80 | 1 | NR | 4 | |
| 15 | M0 | 75 | > 95 | 1 | NR | 3 | |
| 16 | M2 | 18 | 3 | 1 | CR 3 mo | 10 | |
| 17 | M4 | 75 | > 95 | 1 | NR | 11.5 | |
| 18 | M1 | 85 | 90 | 1 | NR | 4 | |
| 19 | M1 | 80 | 20 | 2 | PR | 12.5 + | |
| 900 | 20 | M1 | 60 | 25 | 3 | PR | 11 + |
| 21 | Ph + ALL | 70 | > 95 | 1 | NR | 5 | |
| 22 | M5 | > 95 | > 95 | 1 | NR | 2 | |
| 23 | CML-BC | 27 | 14 | 1 | PR | 11 + | |
| 24 | M2 | 25 | 25 | 1 | NR | 10.5 + | |
| 25 | Ph + ALL | 90 | 90 | 1 | NR | 0.5 | |
| 26 | M5 | 35 | 35 | 1 | NR | 7.5 | |
| 27 | M4 | 27 | 8.5 | 3 | PR | 9 | |
| 28 | M0 | NE | NE | 1 | NR | 1.5 | |
| 29 | M0 | 75 | 95 | 1 | NR | 2 | |
| 30 | M1 | 50 | 25 | PR | 5 | ||
| 1200 | 31 | M4 | 85 | — | 1 | Neurotoxicity | 3 |
| 32 | M4 | 60 | — | 1 | Neurotoxicity | 5 | |
| 33 | M0 | 90 | — | 1 | Neurotoxicity | 9.5 + | |
| 34 | L2 | 90 | 100 | 1 | NR | 3 | |
| R115777 dose (mg) . | Patient no. . | Diagnosis . | % Marrow blasts . | Total no. courses . | Clinical outcome . | Survival from R115777 (mo) . | |
|---|---|---|---|---|---|---|---|
| Pre-Rx . | End . | ||||||
| 100 | 1 | M5 | 95 | 95 | 1 | NR | 2.5 |
| 2 | M1 | 37 | 4 | 3 | CR 7 mo | 15 + | |
| 3 | CML-BC | 37 | 51 | 1 | NR | 6 | |
| 4 | M7 ? | NE | NE | 1 | NR | 5 | |
| 5 | M1 | 100 | 100 | 1 | NR | 1 | |
| 6 | M1 | 20 | 8 | 4 | PR | 14 + | |
| 300 | 7 | CML-BC | 39 | 7 | 3 | PR | 14.5 + |
| 8 | Ph + L2 | 80 | > 95 | 1 | NR | 5 | |
| 9 | L2 | 39 | 86 | 1 | NR | 1.5 | |
| 10 | M4 | 25 | 8 | 4 | PR | 7 | |
| 11 | M7 | 25 | 25 | 3 | NR | 5.5 | |
| 600 | 12 | M1 | 36 | 88 | 1 | NR | 0.5 |
| 13 | M4 | 83 | 64 | 1 | NR | 7 | |
| 14 | L2 | 90 | 80 | 1 | NR | 4 | |
| 15 | M0 | 75 | > 95 | 1 | NR | 3 | |
| 16 | M2 | 18 | 3 | 1 | CR 3 mo | 10 | |
| 17 | M4 | 75 | > 95 | 1 | NR | 11.5 | |
| 18 | M1 | 85 | 90 | 1 | NR | 4 | |
| 19 | M1 | 80 | 20 | 2 | PR | 12.5 + | |
| 900 | 20 | M1 | 60 | 25 | 3 | PR | 11 + |
| 21 | Ph + ALL | 70 | > 95 | 1 | NR | 5 | |
| 22 | M5 | > 95 | > 95 | 1 | NR | 2 | |
| 23 | CML-BC | 27 | 14 | 1 | PR | 11 + | |
| 24 | M2 | 25 | 25 | 1 | NR | 10.5 + | |
| 25 | Ph + ALL | 90 | 90 | 1 | NR | 0.5 | |
| 26 | M5 | 35 | 35 | 1 | NR | 7.5 | |
| 27 | M4 | 27 | 8.5 | 3 | PR | 9 | |
| 28 | M0 | NE | NE | 1 | NR | 1.5 | |
| 29 | M0 | 75 | 95 | 1 | NR | 2 | |
| 30 | M1 | 50 | 25 | PR | 5 | ||
| 1200 | 31 | M4 | 85 | — | 1 | Neurotoxicity | 3 |
| 32 | M4 | 60 | — | 1 | Neurotoxicity | 5 | |
| 33 | M0 | 90 | — | 1 | Neurotoxicity | 9.5 + | |
| 34 | L2 | 90 | 100 | 1 | NR | 3 | |
For abbreviations, see Table 1.
As of 10/15/2000.